IRVINE, Calif.--(BUSINESS WIRE)--June 14, 2006--Cobalis Corp. (OTC BB: CLSC - News), a pharmaceutical development company focused on the treatment of allergy and other atopic conditions, today announced it intends to initiate two identical, Phase III Clinical Trials of its anti-allergy medication PreHistin® in patients with seasonal allergic rhinitis. The randomized, double blind, placebo-controlled studies are intended to assess the efficacy, overall safety and tolerability of Cobalis’ flagship drug PreHistin to prevent the onset and reduce the severity of allergy symptoms.
